scispace - formally typeset
J

Jun-ichi Hanai

Researcher at Beth Israel Deaconess Medical Center

Publications -  56
Citations -  10141

Jun-ichi Hanai is an academic researcher from Beth Israel Deaconess Medical Center. The author has contributed to research in topics: SMAD & Transactivation. The author has an hindex of 35, co-authored 56 publications receiving 9429 citations. Previous affiliations of Jun-ichi Hanai include Harvard University & Japan Society for the Promotion of Science.

Papers
More filters
Journal ArticleDOI

Design and synthesis of emodin derivatives as novel inhibitors of ATP-citrate lyase

TL;DR: Computational modeling indicates a new class of ACL inhibitors bearing the key structural feature of the natural product emodin occupies an allosteric binding site and blocks the entrance of the substrate citrate to its binding site.
Journal ArticleDOI

Embryonic Senescence and Laminopathies in a Progeroid Zebrafish Model

TL;DR: New zebrafish models for a human premature aging disorder are generated and the utility for studying laminopathies is demonstrated, which may provide a new platform for future drug screening as well as genetic analyses aimed at identifying modifier genes that influence not only progeria and laminationopathies but also other age-associated human diseases common in vertebrates.
Journal ArticleDOI

Intracellular signaling of the TGF-beta superfamily by Smad proteins.

TL;DR: The recent study demonstrated that Smads exist as monomers in the absence of TGF‐β, and a missense mutation of Smad2 identified in colorectal and lung cancers was introduced to Smad3, which could actively contribute to oncogenesis.
Journal ArticleDOI

Parathyroid hormone controls paracellular Ca2+ transport in the thick ascending limb by regulating the tight-junction protein Claudin14

TL;DR: PTH1R signaling directly and indirectly regulates the paracellular Ca2+ transport pathway by modulating Cldn14 expression in the TAL, suggesting that down-regulation of Claudin14 could provide a potential treatment option to correct urinary Ca2- loss, particularly in patients with hypoparathyroidism.